Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Oral factor Xa inhibitors are widely used for anticoagulation.
• There is a lack of approved reversal agents for these anticoagulants.
• Prothrombin complex concentrate (PCC) has been explored for managing bleeding associated with factor Xa inhibitors.

Purpose of the Study:

• To evaluate the effectiveness and safety of a fixed dose of PCC in patients experiencing major bleeding while on oral factor Xa inhibitors.
• To assess the hemostatic effectiveness and adverse events following PCC administration.

Main Methods:

• A cohort of 66 patients with major bleeding on apixaban or rivaroxaban received 2,000 units of PCC.
• Physicians assessed hemostatic effectiveness as good, moderate, or poor/none.
• Safety outcomes included thromboembolism and death over a 30-day follow-up.
• A post hoc analysis used International Society on Thrombosis and Haemostasis criteria for reversal effectiveness.

Main Results:

• PCC was assessed as effective (good or moderate) in 85% of patients.
• Specifically, 65% had good effectiveness, 20% moderate, and 15% poor/none.
• In a post hoc analysis, reversal was effective in 68% of patients.
• The 30-day mortality rate was 14%, with 8% experiencing major thromboembolic events.

Conclusions:

• Prothrombin complex concentrate (PCC) may offer a beneficial effect in managing major bleeding associated with oral factor Xa inhibitors.
• The potential risk of thromboembolism following anticoagulation reversal in patients with a prothrombotic background must be considered.